Literature DB >> 8706348

Histaminergic regulation of interferon-gamma (IFN-gamma) production by human natural killer (NK) cells.

A Asea1, M Hansson, C Czerkinsky, T Houze, S Hermodsson, O Strannegård, K Hellstrand.   

Abstract

Monocytes, recovered from human peripheral blood by counter-current centrifugal elutriation, effectively inhibit the production of IFN-gamma by CD3-/56+ NK cells in response to IL-2. This study aimed at defining the nature of the inhibitory signal, particularly the importance of monocyte-derived reactive metabolites of oxygen. It was found that monocytes recovered from patients with chronic granulomatous disease (CGD), a condition characterized by deficient NADPH-oxidase activity of phagocytes, did not inhibit IFN-gamma production by NK cells. Further, catalase, a scavenger of hydrogen peroxide, completely reversed the inhibitory signal whereas scavengers of the superoxide anion, hypohalous acids, the hydroxyl radical, or nitric oxide synthesis inhibitors such as L-NMMA were ineffective. Inhibition of IFN-gamma production was operating on a pretranslational level, as indicated by the inability of enriched NK cells to accumulate IFN-gamma mRNA in the presence of elutriated monocytes. Hydrogen peroxide, at micromolar concentrations, reconstituted the inhibition of IFN-gamma production when added to enriched NK cells. Histamine, a biogenic amine which inhibits the generation of reactive oxygen metabolites in monocytes, abrogated the inhibition of IFN-gamma production in NK cells; by this mechanism, histamine strongly synergized with IL-2 to induce IFN-gamma in mixtures of NK cells and monocytes. The synergizing effect of histamine was specifically mediated by H2-type histamine receptors. We conclude that: (i) the induction of IFN-gamma mRNA in NK cells is effectively down-regulated by products of the oxidative metabolism of monocytes; and (ii) histamine effectively enhances IFN-gamma production by preventing monocyte-induced oxidative damage to NK cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706348      PMCID: PMC2200497          DOI: 10.1046/j.1365-2249.1996.d01-755.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  3 in total

Review 1.  Alleviating oxidative stress in cancer immunotherapy: a role for histamine?

Authors:  K Hellstrand; M Brune; C Dahlgren; M Hansson; S Hermodsson; P Lindnér; U H Mellqvist; P Naredi
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

2.  HSP70 peptidembearing and peptide-negative preparations act as chaperokines.

Authors:  A Asea; E Kabingu; M A Stevenson; S K Calderwood
Journal:  Cell Stress Chaperones       Date:  2000-11       Impact factor: 3.667

3.  Histamine dihydrochloride protects against early alcohol-induced liver injury in a rat model.

Authors:  Stephen C Hornyak; Kurt R Gehlsen; Tapio Haaparanta
Journal:  Inflammation       Date:  2003-10       Impact factor: 4.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.